Clinical Trials authorized in Uganda since 2016 – Updated on 11th January 2022

SNCTA #TitleDate of initial AuthorizationPrincipal InvestigatorInstitutionSponsorStatusDuration of the trial
1.       0001Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-center, parallel-group, two arm randomized placebo controlled superiority trial.4/4/2016Dr. Robert Opoka OpokaDepartment of Pediatrics and Child Health, MUCHS Liverpool School of Tropical Medicine (LSTM)Closed Out
2.       0002Doxycycline for the treatment of nodding syndrome: A phase II, randomized placebo controlled trial.4/5/2016Dr. Richard IdroDepartment of Pediatrics and Child Health, MUCHSOngoing
3.       0003Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability, and Anti-Retroviral Activity of GSK 1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents. (IMPAACT P1093)5/19/2016Dr. Linda Barlow MoshaMU-JHU Care Ltd.United States National Institute of HealthOngoing
4.       0004Prevention of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 3)8/9/2016Prof. Moses KamyaMU-UCSFClosed Out
5.       0005A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS -9883/ Emtricitabine/Tenofovir Alafenamide (GS - 9883/F/TAF) from Elvitegravir /Cobicistat /Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF), or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumerate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women.5/11/2016Dr. Cissy Kityo MutuluzaJoint Clinical Research CentreOngoing
6.       0006A randomized trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART. (ODYSSEY PENTA 20)7/15/2016Dr. Cissy Kityo MutuluzaJoint Clinical Research CentreOngoing
7.       0007Pharmacokinetics of efavirenz 400 mg once daily during pregnancy in HIV -1 infected women.7/7/2016Dr. Mohammed LamordeInfectious Diseases InstituteClosed out
8.       0008Investigation of rheumatic AF Treatment Using Vitamin K antagonists, rivaroxaban or aspirin Studies. (INVICTUS) 12/12/2016Dr. Emmy OkelloUganda Heart InstitutePopulation Health Research InstituteOngoing
9.       0009A Multi-center, Phase 3B Open-label Follow-up trial to assess the continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women. (MTN 025)9/5/2016Dr. Brenda Gati MirembeMUJHU Care Ltd.Division of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH)Closed out
10.   0010A Multi-country, prospective, clinical safety study of subjects exposed to the candidate Ebola vaccines Ad26.ZEBOV and/or MVA –BN-Filo.9/2/2016Prof. Pontiano KaleebuMRC/UVRIJanssen VaccineOngoing
11.   0011A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Women.3/10/2017Dr. Mohammed LamordeInfectious Diseases InstituteOngoing
12.   0012A multicenter, open label , randomized , multiple dose , two period crossover, bioequivalence study of Liposomal Amphotericin B injection (Cipla Ltd. , India) and AmBisome® Liposome for injection (Gilead life sciences, USA ) in adult patients with fungal infections. 11/1/2016Dr. Henry MugerwaJoint Clinical Research CentreClosed out
13.   0013A Follow-Up Open Label Trial to Assess The Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy HIV-Negative Women (Phase IIIb)10/10/2016Dr. Sylvia KusemererwaMRC/UVRIClosed-out
14.   0014Strategy for Maintenance of HIV Suppression with Elvitegravir + Darunavir +Ritonavir in Children. (SMILE PROTOCOL)2/6/2017Dr. Victor MusiimeJoint Clinical Research CentrePENTA FoundationAmended to CTA0065
15.   0015Defining the Molecular profile of Breast Cancer in Uganda and its Clinical Implications3/2/2017Dr. Jackson OremUganda Cancer InstituteGSKOngoing36 Months
16.   0016Optimizing Hydroxyurea Therapy in Children with Sickle Cell Anemia in Malaria Endemic Areas : The NOHARM Maximum Tolerated Dose (MTD) Extension Study3/28/2017Dr. Robert Opika OpokaGlobal Health Uganda / Pediatric Department, Mulago Hospital Doris Duke Chariatable FoundationOngoing
17.   0017The effect of modified F-75 on diarrhea in the treatment of children with severe acute malnutrition.1/31/2017Dr. Elizabeth KibonekaMwana Mugimu Nutrition Unit, Mulago HospitalUniversity of CopenhagenTerminated
18.   0018A Phase 2/3 , Open Label Study of the Pharmacokinetics , Safety, and Antiviral Activity of the GS-9883/ Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) in HIV-1 infected Virologically Suppressed Adolescents and Children3/17/2017Dr. Eva NatukundaJoint Clinical Research CentreGilead SciencesOngoing
19.   0019Anti-retroviral therapy for acute HIV infection2/15/2018Dr. Francis KiweewaMakerere University Walter Reed Project.Henry M Jackson Foundation,United States Military HIV Research ProgramClosed out24 Months
20.   0021An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccines from EV06 trial3/10/2017Prof. Pontiano KaleebuMRC/UVRIHenry M Jackson Foundation, PEPFARClosed out
21.   0022Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (CREOLE)5/31/2017Dr. Mondo Charles KiizaSt. Francis Hospital NsambyaUniversity of AbujaTBC36 Months
22.   0023Phase 1 Safety and Pharmacokinetic Study of Maraviroc in HIV-1- Exposed Infants at Risk of Acquiring HIV-I Infection6/14/2017Dr. Jesca NakibuukaMU-JHU Care Ltd.Division of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH)Withdrawn28 Months
23.   0024Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial4/26/2017Dr. Cissy Kityo MutuluuzaJoint Clinical Research CentreOngoing
24.   0025An international multi-center controlled clinical trial to evaluate 1200mg and 1800mg rifampicin daily in the reduction of treatment duration for pulmonary tuberculosis from 6 months to 4 months (Rifashort)6/14/2017Dr. Daniel AtwineEpicentre - Mbarara Research BaseSt George University of LondonOngoing36 Months
25. 0026Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis among Women at High Risk for HIV infection in Kampala, Uganda 3/29/2017Prof. Janet SeeleyMRC/UVRILondon School of Hygiene and Tropical MedicineOngoing
26.   0027The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB (STREAM)5/23/2017Dr. Bruce KirengaMakerere University – Lung InstituteThe International Union Against the TB and Lung Disease (IUATLD)Ongoing60 Months
27.   0028Assessing the tolerability and safety of single low dose Primaquine in African Children with Acute Uncomplicated Falciparum Malaria and Glucose-6-Phoasphate Dehydrogenase Deficiency.6/22/2017Dr. Peter Olupot-OlupotMbale Clinical Research InstituteMahidol Oxford Research Unit-University of OxfordOngoing60 Months
28.   0029First line Antimicrobials in Children with complicated Severe Acute Malnutrition. (FLACSAM)6/22/2017Dr. Peter Olupot-OlupotMbale Clinical Research InstituteOxford UniversityOngoing36 Months
29.   0030IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir Containing versus Efavirenz Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants.9/29/2017Dr. Deo WabwireMU-JHU Care Ltd.Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID)Ongoing48 Months
30.   0031Randomized clinical trial evaluating sertraline plus fluconazole verses fluconazole alone for pre-emptive treatment of asymptomatic cryptococcal antigenemia in HIV-Infected persons living with AIDS.8/11/2017Dr. David MeyaInfectious Diseases InstituteOngoing48 Months
31.   0032IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir –Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1 Infected Pregnant Women and their Infants10/20/2017Dr. Violet KorutaroBaylor College of Medicine Children’s Foundation UgandaDivision of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIH)Ongoing48 Months
32.   0033HPTN084: A Phase 3 Double Blind Safety and Efficacy Study of Long Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV- Uninfected Women.10/13/2017Dr. Clemensia NakabiitoMU-JHU Care Ltd.Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH),Ongoing60 Months
33.   0034A Randomized, blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines (YEFE)10/4/2017Dr. Maria Loiuse NamulwanaEpicentre - Mbarara Research BaseRebecca Grais, Director Research EpicenterClosed out48 Months
34.   0035Randomized Trial to Prevent Vascular Events in HIV-REPRIEVE. Protocol No: A53329/27/2017Prof. Cissy Kityo MutuluuzaJoint Clinical Research CentreDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH),Ongoing96 Months
35.   0036Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses12/11/2017Dr Cissy KityoJoint Clinical Research CentreNational Institute of Allergy and Infectious Diseases (NIAID)Closed-out18 Months
36.   0037A Phase II interventional multi-center randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersible Formulation in the combination given once daily for 1,2 and 3 days to adults and children with uncomplicated Plasmodium Falciparum Malaria. 3/9/2018Dr. Adoke YekaInfectious Diseases Research CollaborationNovartis Pharma AGOngoing36 Months
37.   0038A Phase II interventional multi-center randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersible Formulation in the combination given once daily for 1,2,and 3 days to adults and children with uncomplicated Plasmodium Falciparum Malaria1/10/2018Dr. Sylvia KusemererwaMRC/UVRINovartis PharmaceuticalsOngoing36 Months
38.   0039Optimizing iron status while minimizing morbidity in HIV-Infected Ugandan Children1/3/2018Dr. Victor MusiimeJoint Clinical Research CentreUniversity of Minnesota Msonic Cross-Departmental Grants for Children’s Health ResearchOngoing36 Months
39.   0040An open Label Phase III Randomized Controlled Multicenter Non inferiority Trial to compare Efficacy and Safety of Miltefosine and Paramomycin with Sodium Stigbogluconate and Paramomycin combination for the treatment of Primary Visceral Leishmaniasis (VL) patients in East Africa.1/22/2018Prof. Joseph OloboDepartment of Immunology and Molecular Biology, Makerere UniversityDrugs For Neglected Diseases InitiativeClosed out
40.   0041Testing the ability of a microbiome-focused intervention to reduce HIV susceptibility in Ugandan men. Protocol No: TmHIV-0110/17/2017Dr. Bernard S. BagayaUVRI-IAVI HIV Vaccine ProgramCanadia Institute of Health Research (CIHR)Ongoing31 Months
41.   0042Dolutegravir in Pregnant HIV Mother and their Neonates (DOLPHIN-2)12/12/2017Dr. Mohammed LamordeInfectious Diseases InstituteUniversity of LiverpoolOngoing
42.   0043A Pilot Study of Nelfinavir for the Treatment of Kaposi’s Sarcoma (AmC 098).10/16/2018Dr. Jackson OremUganda Cancer InstituteAIDS Malignancy ConsortiumOngoing36 Months
43.   0044A phase 2a Crossover Trial to Evaluate the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population.7/9/2018Dr. Carolyne Agwau AkelloMU-JHU Research CollaborationDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Health (NIH)Ongoing36 Months
44.   0045Steady-state pharmacokinetics of Efavirenz (Stocrin) 400 mg once daily in the presence of rifampicin and isoniazid (Rifinah or the local generics). Protocol SSAT0621/3/2018Dr. Mohammed LamordeInfectious Diseases InstituteSt Stephens' AIDS Trust, LondonClosed out24 Months
45.   0046HIV Self-testing to empower Prevention Choices in Sex workers.1/3/2018Dr. Andrew MujugiraInfectious Diseases InstituteForgaty International CenterOngoing9 Months
46.   0047A Randomized, Double-Blind, Efficacy and Safety Study of Azilsartan Medoxomil Treatment and Withdrawal, followed by Open-Label Extension, in Children 6 to Less Than 18 Years of Age with Hypertension .N/ADr. Henry MugerwaJoint Clinical Research CenterRejected58 Months
47.   0048Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to reduce TB burden11/8/2018Prof. Moses KamyaInfectious Diseases Research CollaborationNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing36 Months
48.   0049A phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women. (HPTN 084)4/4/2018Dr. Patricia Nahirya NtegeBaylor College of Medicine Children’s FoundationDivision of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), US National Institute of Health (NIH)Ongoing54 Months
49.   0050A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria3/6/2018Dr. Henry MugerwaJoint Clinical Research CentreNovartis Pharma AGClosed out18 Months
50.   0051A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria2/28/2018Dr. Stephen AsiimweKabwohe Clinical Research CentreNovartis Pharma AGClosed Out18 Months
51.   0052A Phase 2, Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)ide Reverse Transcriptase Inhibitor-Containing Regimen with Nucloes(t)ide Transcriptase Inhibitor Resistant Virus, Followed by Continued Treatment with a GS-9131+Bictegravir+Darunavir+Ritonavir Regimen. Protocol Number: GS-US-442-41482/6/2018Dr. Cissy Kityo MutuluuzaJoint Clinical Research CentreGilead SciencesOngoing30 Months
52.   0053HIV Self-Testing and PrEP to Increase Testing and Prevention Uptake among Male Partners and improve postpartum ART Use in PMTCT B+ Programs in Uganda1/3/2018Professor Elly KatabiraInfectious Diseases InstituteUS National Institute of Mental HealthOngoing
53.   0054Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women.4/17/2018Professor Elly KatabiraInfectious Diseases InstituteUniversity of Washington,Ongoing42 Months
54.   0055A Pharmacokinetic Evaluation of Etonogestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-Based Antiretroviral Therapy. (DRIVE-1)6/26/2018Prof. Mohammed LamordeInfectious Diseases InstituteInfectious Diseases InstituteOngoing24 Months
55.   0056A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir versus Rilpivirine-based Antiretroviral Therapy. (DRIVE-2)6/27/2018Prof. Mohammed LamordeInfectious Diseases InstituteInfectious Diseases InstituteOngoing24 Months
56.   0057A Phase 2, multicenter, randomized open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria.3/1/2018Dr. Adoke YekaInfectious Diseases Research CollaborationNovartisClosed Out18 Months
57.   0058A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV Uninfected Women4/4/2018Dr. Juliet MpendoUganda Virus Research Institute-International AIDS Vaccine InitiativeDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH)Ongoing56 Months
58.   0060Integrated PrEP and ART delivered in Ugandan public health clinics to improve HIV and ART outcomes for HIV serodiscordant couples.6/21/2018Prof. Elly KatabiraInfectious Diseases InstituteUniversity of WashingtonOngoing
59.   0061High-Dose Intravenous Rifampicin to Improve Survival of Tuberculosis Meningitis: A phase II open-label randomized controlled trial (RifT Study).6/18/2018Dr. David B. MeyaInfectious Diseases InstituteInfectious Diseases InstituteOngoing36 Months
60.   0062IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants.6/22/2018Dr. Clemensia NakabiitoMUJHU Research CollaborationNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing9 Months
61.   0063EMaBS TB Vaccine Study: Open label, dose escalation and age de-escalation for ChAdox1 85A in Ugandan adults and adolescents, followed by a Phase IIa randomized, open-label trial among adolescents comparing ChAdOx1 85A prime followed by MVA85A boost versus BCG re-vaccination. 7/20/2018Prof. Alison ElliotMRC/UVRI and LSHTM Uganda Research UnitUniversity of Oxford Clinical Trials and Research Governance Joint Research OfficeOngoing30 Months
62.   0064High Dose AMBISOME on a fluconazole backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Phase 3 Randomized Non- Inferiority Trial (AMBITION-CM).6/22/2018Dr. David MeyaInfectious Diseases InstituteLondon School of Hygiene and Tropical Medicine (LSHTM)Ongoing48 Months
63.   0065A Phase 2/3 Multi-center, Open-label, Randomized study evaluating the Safety and Anti-viral effect of once daily integrase inhibitor administered with Darunavir/ritonavir (DRV/r) compared to current Standard of Care (SOC) antiretroviral therapy in HIV-1 infected, virologically suppressed Pediatric participants. 6/22/2018Dr. Victor MusiimeJoint Clinical Research CentrePENTA FoundationOngoing72 Months
64.   0066Children with HIV in Africa - Pharmacokinetics and Acceptability of Simple Second-line Anti-Retroviral Regimens.7/29/2018Dr. Victor MusiimeJoint Clinical Research CentreUniversity College of LondonOngoing60 Months
65.   0067Efficacy and Safety of Artemether-Lumefantrine, Artesunate-Amodiaquine and Dihydroartemisinin-Piperaquine for The Treatment of Uncomplicated Plasmodium Falciparum Malaria in Uganda.7/4/2018Dr. Adoke YekaInfectious Diseases Research CollaborationNational Malaria Consortium Program, MOH, WHO Country officeOngoing21 Months
66.   0068“GwokO Adunu pa Lutino” (GOAL Trial) – Determining the Impact of Penicillin on Latent Rheumatic Heart Disease: A Randomized Controlled Trial8/20/2018Dr. Emmy OkelloUganda Heart InstituteChildren’s National Medical CentreOngoing36 Months
67.   0069Encochleated Oral Amphotericin for Cryptococcal Meningitis. (EnACT)10/4/2018Dr. David B. MeyaInfectious Diseases InstituteMatinaas Biopharma Nanotechnologies, Inc USAOngoing24 Months
68.   0070A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of an Ebola Sudan Chimpanzee Adenovirus Vector Vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), in Healthy Adults.11/26/2018Dr. Betty MwesigwaMakerere University Walter Reed ProjectNational Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH), Vaccine Research Centre (VRC) Bethesda, MarylandOngoing24 Months
69.   0071Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS)8/23/2018Dr. Robert OpokaDepartment of Pediatrics and Child Health, MUCHSThrasher Research FundOngoing12 Months
70.   0072An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSV?G-ZEBOV-GP. 9/21/2018Dr. Juliet Mwanga AmumpaireEpicenter Mbarara Research CenterMedicins Sans FrontieresOngoingUndetermined
71.   0073A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo, Phase 3.11/2/2018Dr. Hannah KibuukaMakerere University Walter Reed ProjectJanssen Vaccines and Prevention B.VOngoing60 Months
72.   0074A Randomized, Placebo-controlled Trial of HPV vaccination to reduce Cervical High-Grade Squamous Intraepithelial Lesions among HIV-infected Women Participating in an HPV Test-and-Treat Program. (CONVENANT)12/10/2018Dr. Jackson OremUganda Cancer InstituteNational Cancer Institute, Office of HIV and AIDS MalignancyTBC60 Months
73.   0075Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old in Uganda.10/12/2018Dr. Irene LubegaInfectious Diseases InstituteCentre For Disease Control and PreventionOngoing36 Months
74.   0076A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavarin-free HCV Therapy to HCV Infected Populations who are HCV Treatment Naïve with Evidence of Active HCV Infection.11/26/2018Dr. Cissy KityoJoint Clinical Research CentreNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing30 Months
75.   0077An Open-label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4 Month Treatment of Bedaquiline plus Pretomanid plus Moxifloxacin plus Pyrazinamide (BPaMZ) Compared to a 6 Month Treatment of HRZE/HR (Control) in Adult Participants with Drug- Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants with Drug-Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)12/4/2018Prof. Harriet Mayanja KizzaCase Western Reserve University Research Collaboration (CWRU)Global Alliance for TB Drug DevelopmentOngoing36 Months
76.   0078A Phase 2, Open-label, Multicenter, Single arm study to evaluate the Pharmacokinetics, Safety, Tolerability and Anti-Mycobacterial activity of TCM207 in combination with a Background regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the treatment of children and adolescents 0 months to <18 years of age who have Confirmed or Probable Pulmonary MDR-TB Protocol TMC207-C211 9/12/2019Dr. Rebecca NantandaMUCHS, Lung InstituteJanssen PharmaceuticalsOngoing60 Months
77.   0079A Randomized, Double-Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease. (HESTIA3) 1/23/2019Dr. Victor MusiimeJoint Clinical Research CentreAstra Zeneca AB, SwedenTerminated24 Months
78.   0080Pharmacokinetic and Pharmacodynamic Evaluation of Etonogesterol Dose Escalation with Efavirenz based Antiretroviral Therapy in HIV-infected Ugandan Women. (PK-20)1/7/2019Dr. Mohammed LamordeInfectious Diseases instituteUniversity of PitsburgOngoing36 Months
79.   0081Compassionate healthcare and frontline workers and ring vaccination project intended to evaluate safety of the Ebola vaccine in Uganda. Version 1 Expanded Access-Uganda11/26/2018Dr. Bernard OparMinistry of Health Uganda supported by the World Health OrganizationWorld Health OrganizationTerminated
80.   0084IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants.11/26/2018Dr. Nicolette Nabukeera BarungiBaylor College of Medicine Children’s FoundationNational Institute of Allergy and Infectious Diseases (NIAID)Ongoing36 Months
81.   0086“Randomized trial to compare Magnesium Sulphate administration for preeclampsia and eclampsia: Springfusor versus standard approach1/18/2019Dr. Sam OnongeDepartment of Obstetrics and Gynecology, Makerere University College of Health SciencesMakerere University College of Health SciencesOngoing24 Months
82.   0087A Randomized, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease. (HESTIA3)1/30/2019Dr. Kibuuka AfiziInfectious Diseases Research CollaborationAstra ZenecaNot Initiated24 Months
83.   0088Effect of preoperative bicarbonate on Maternal and Perinatal outcomes of obstructed labor; A Study Protocol for a Randomized Controlled Trial1/23/2019Dr. Milton Musaba WambokoDepartment of Obstetrics and Gynecology, Makerere University College of Health SciencesSurvival Pluss Project NORA/NORHED ProgramClosed Out12 Months
84.   0089A Randomized, Four-arm Open-Label Phase IIb Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected patients on Efavirenz-or Dolutegravir based Antiretroviral Therapy. (SAEFRIF) 3/15/2019Dr. Christine SekaggyaInfectious Diseases Institute,Infectious Diseases InstituteOngoing
85.   0090A Phase I/II, Open-Label, Randomized Crossover Pharmacokinetic, Safety and Acceptability Study of the Abacavir/Lamivudine/Lopinavir/Ritonavir/ - 30/15/40/10mg (4-in-1) Fixed Dose Combination vs Lopinavir/Ritonavir - 40/10mg pellets plus Dual Abacavir/Lamivudine - 60/30mg Tablets in HIV Infected Children.1/20/2019Dr. Victor MusiimeJoint Clinical Research CentreDrugs for Neglected Diseases Initiative (DNDI) SwitzerlandEarly Termination by the Sponsor12 Months
86.   0091Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia. (ACACIA)4/23/2019Dr. David MeyaInfectious Diseases InstituteInfectious Diseases InstituteOngoing60 Months
87.   0092Optimizing benefits while reducing risks of iron in malaria-endemic areas: The OptiM3/15/2019Dr. Ezekiel MupereDepartment of Pediatrics and Child healthUniversity of MinnesotaOngoing
88.   0093Population Difference in Vaccine Response: The Role, Reversibility and Mediators of Immunomodulation by Chronic Infections in the Tropics (POPVAC).” – Protocol A: The Effect of Intensive Treatment for Schistosomiasis on Response to Vaccines among Island Adolescents.5/28/2019Prof. Alison ElliotMRC-UVRI and LSHTMMedical Research CouncilOngoing48 Months
89.   0094Population Difference in Vaccine Response: The Role, Reversibility and Mediators of Immunomodulation by Chronic Infections in the Tropics (POPVAC).” – Protocol C: The Impact of BCG ‘Pre-Immunization’ on the Response to Vaccines among Ugandan Adolescents Participating in the Entebbe Mother and Baby Study.5/28/2019Prof. Alison ElliotMRC-UVRI and LSHTMLondon School of Hygiene and Tropical MedicineOngoing36 Months
90.   0095A Randomized, Open-label, Parallel-group, Single Dose Regimen, Phase 2a Study to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination with Ferroquine (FQ) and FQ Alone, in African Patients with Uncomplicated Plasmodium Falciparum Malaria.5/2/2019Dr. Adoke YekaInfectious Diseases Research CollaborationSanofi-Aventis Recherche and Development; Medicines Malaria Venture (MMV)Ongoing24 Months
91.   0096Trial of Faropenem and Cefadroxil (in Combination with Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients with Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers.5/16/2019Dr. Cissy KityoJoint Clinical Research CentreNational University Hospital, 5 lower Kent Ridge Rd SingaporeClosed out3-4 Months
92.   0098Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Other Transfusion Transmitted Infections (Uganda Mirasol Trial).7/4/2019Dr. Irene LubegaMU-JHUDepartment of Defence, Congressionally Directed Medical Research ProgrammeOngoing42 Months
93.   0099Pharmacokinetics ad Pharmacodynamics of Azithromycin in Severe Malaria Bacterial Co-infection in African Children: TABS PKPD Study11/25/2019Prof. Peter Olupot-OlupotMbale Clinical Research InstituteImperial College London. AIMI Vanden OevenOngoing18 Months
94.   0100Monitored Emergency Use of Unregistered and Experimental Drugs (MEURI): Favipiravir for Exposed Staff to Filovirus (Marbug and Ebola) in Uganda6/18/2019Prof. Juliet Mwanga AmumpaireMSF Epicenter MbararaMedicines Sans FrontieresOngoingUndetermined
95.   0101Nucleosides and Darunavir/Dolutegravir in Africa (The NADIA Trial): A Randomised Controlled Trial of Darunavir versus Dolutegravir and Tenofovir versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa6/11/2019Dr. Andrew KambuguInfectious Diseases InstituteInfectious Diseases InstituteOngoing36 Months
96.   0102A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined with Local Standard of Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as a Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Children, Adolescents and Adults in Uganda4/7/2019Dr. Henry DdunguUCIFred Hutchinson Cancer Research CentreOngoing48 Months
97.   0103A Randomized, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagleror versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease6/11/2019Dr. Sylvia KusemererwaMRC/UVRI and LSHTMAstra Zeneca ABTerminated24 Months
98.   0104A Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® with or without AP 10-701 for Intestinal Schistosomiasis in Healthy Ugandan Adults.8/28/2019Dr. Hannah KibuukaMUWRPBaylor College of MedicineOngoing36 Months
99.   0105Monitored Emergency Use for Ebola Virus Disease6/18/2019Dr. Francis KiweewaMUWRPJoint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) programClosed Out36 Months
100.        0106An open-label, single arm study to provide additional information on immunogenicity and safety of Ad26.ZEBOV/MVA-BN-Filo6/19/2019Prof. Pontiano KaleebuMRC/UVRI and LSHTMLondon School of Hygiene and Tropical Medicine LSHTMOngoingUndetermined
101.        0107Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis (TRUNCATE-TB).8/16/2019Dr. Christine Sekaggya-WiltshireInfectious Diseases InstituteUniversity College London.Ongoing36 Months
102.        0108Remdesivir (GS-5734): Monitored Emergency Use for Ebola Virus Disease.6/18/2019Dr. Bernard OparMinistry of HealthMedicines Sans FrontieresOngoingUndetermined
103.        0109REGN3470-3471-3479: Monitored Emergency Use for Ebola virus Disease.6/18/2019Dr. Bernard OparMinistry of HealthMedicines Sans FrontieresOngoingUndetermined
104.        0110ZMapp: Monitored Emergency Use for Ebola Virus Disease. Version 1.0 dated 16 December 2018. (ZMAPP)6/18/2019Dr. Bernard OparMinistry of HealthMedicines Sans FrontieresOngoingUndetermined
105.        0111A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumarate Switched to Tenofovir Alafenamide Fumarate based Anti-Retroviral Therapy. (BONE STAR)9/4/2019Dr. Flavia Matovu KiweewaMU-JHU Research CollaborationGilead SciencesOngoing36 Months
106.        0112Combined HIV Adolescent PrEP and Prevention: On Demand Pre-Exposure Prophylaxis to Provide Protection from HIV in Men using Foreskin Tissue to Estimate Protection (CHAPS II)9/19/2019Dr. Pontiano KaleebuMRC/UVRI and LSHTM Uganda Research InstitutePerinatal HIV Research Unit, Chris Hani Bagwaranth Academic Hospital, University of Witswater Rand UniversityClosed-out12 Months
107.        0113Non-Inferiority Fractional-Doses Trial for Yellow Fever Vaccine. (NIFTY)9/23/2019Dr. Maria Louise Namulwana Epicentre Mbarara Research CentreUniversity of Oxford UK. KEMRI-Welcome Trust Research ProgrammeOngoing36 Months
108.        0114Efficacy and Safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicenter, open-label clinical trial 12/27/2019Prof. Enock MatovuMakerere University, College of Veterinary Medicine, Animal Resources and BiosecurityDrugs for Neglected Diseases Initiative DNDIOngoing39 Months
109.        0115A5300B/12003B/PHOENIx: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB)9/27/2019Dr. Henry MugerwaJoint Clinical Research CentreDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID),National Institute of Health (NIH), DHHSOngoing60 Months
110.        0116A5300B/12003B/PHOENIx: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIX MDR-TB), 10/21/2019Dr. Carolyne Peris OnyangoMU-JHUNational Institute of Allergy and Infectious Diseases (NIAID),National Institute of Child Health and Human DevelopmentOngoing60 Months
111.        0117Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic infections in the tropics (POPVAC). – Protocol B: The effect of intermittent preventive treatment for Malaria with dihydroartemisinin –piperaquine on response to vaccines among rural adolescents. (POPVAC-B)9/11/2019Prof. Alison ElliottMRC-UVRI and LSHTMLondon School of Hygiene and Tropical Medicine LSHTMOngoing48 Months
112.        0118High Dose Oral Rifampicin to Improve Survival from Adult Tuberculosis Meningitis: A Double-blinded Randomised Controlled Phase III Trial. (HARVEST)12/23/2019Dr. David MeyaInfectious Diseases InstituteInfectious Diseases InstituteOn-going60 Months
113.        0119Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: A multicenter open label randomized controlled clinical trial (EMPIRICAL)3/11/2020Dr. Victor MusiimeMUCHSServicia Madrileno de Salud (SERMAS)-Fundacion para la Investigacion BiomedicaOngoing36 Months
114.        0120Birth Asphyxia in Uganda: Prevalence, Associated Factors and Effect of Intra-Partum Oxygen Administration on Fetal and Early Neonatal Outcomes. (INTRA-O)12/11/2019Ms. Elizabeth AyebareDepartment of Nursing, School of Health Sciences, Makerere University.Ayebare ElizabethOngoing8 Months
115.        0121Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy. (DELIVER)12/6/2019Dr. Clemensia NakabittoMU-JHUDivision of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH)Ongoing36 Months
116.        0122Impact of Increased Praziquantel Frequency On Childhood Fibrosis in Persistent Schistosmiasis Morbidity Hot Spots (FibroScHot)1/23/2020Dr. Edridah TukahebwaVector Control DivisionCambridge University Hospitals NHS Foundation Trust, The Chancellor, Masters and Scholars of the University of CambridgeOngoing32 Months
117.        0124Safety and efficacy of Dolutegravir and EFV400 for pregnant and breatfeeding women: a randomised non-inferiority clinical trial.5/8/2020Dr. Jackson MukonzoDepartment of Pharmacology and Therapeutics, MAKCHSHawassa UniversityOngoing
118.        0125A phase IIb three-arm, two-stage HIV-1 prophylactic vaccine trial with a second randomisation to compare TAF/FTC in comparison to TDF/FTC as pre-exposure prophylaxis (PrEPVacc)3/26/2020Prof. Pontiano KaleebuMRC/UVRIJonathan Weber, Imperial College, Room 2.15, 2 Floor, Faculty Building, South Kesington campus, Exhibition road, LondonOngoing36 Months
119.        0126A Phase 3, Open-label, Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir administered with Rifampicin to HIV Positive Adults on Second-line ART Regimen with Suppressed HIV-1 Viral Load (DERIVE).5/22/2020Dr. Henry MugerwaJoint Clinical Research CentreUniversity of LiverpoolOngoing18 Months
120.        0128DPART Study Dihydroatemisinin in the context of Antiretroviral Therapy. (DPART)7/30/2020Dr. Grace Paul KisituBaylor College of Medicine , Children’s FoundationNational Institute of Child Health and Human Development (NICHD)Ongoing
121.        0129A multicenter, phase III double blind, randomized active controlled study to evaluate the efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. (VPM)7/8/2020Dr. Victoria NankabirwaMakerere University School of Public HealthSerum Institute of India, Private LimitedOngoing36 Months
122.        0130Phase 3B, Randomized, Open-label, Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in breastfeeding Mother-infant Pairs. Protocol Version 1.0 dated 24 July 2019. (TRUVADA)5/3/2020Dr. Brenda Gati MirembeMU-JHUDivision of AIDS (DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID)Closed-out24 Months
123.        0131ROSuvastatin Evaluation as a Tuberculosis Treatment Adjunct (ROSETTA)7/20/2020Dr. Cissy Kityo MutuluuzaJoint Clinical Research CentreNational University HospitalOngoing11 Months
124.        0132Impact of oral step-down to amoxicillin or co-amoxiclav and of duration of antibiotic therapy on effectiveness, safety and selection of antibiotic resistance in severe childhood community-acquired pneumonia (CAP): a randomized controlled trial. (PediCAP)6/15/2020Dr. Victor MusiimeDepartment of Pediatrics and Child HealthFondazione PENTA ONLUSOngoing24 Months
125.        0133Praziquantel for children under age four years: A phase II PK/PD driven dose finding trial (PIP)7/27/2020Dr. Patrice MawaMRC/UVRI AND LSHTMRhode Island Hospital, Center for International Health ResearchOngoing36 Months
126.        0134Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CABLA) for Prevention of HIV among Female Adolescents-A Sub-study of HPTN084. (CABLA)6/26/2020Dr. Brenda Gati MirembeMU-JHUDivision of AIDS(DAIDS), United States (US) National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), US National Institute of Health (NIHOngoing24 Months
127.        0135Optimal chemopreventive regimens to prevent malaria and improve birth in Uganda, 7/30/2020Prof. Moses KamyaIDRCThe National Institute of Child Health and Human Development (NICHD)Ongoing60 Months
128.        0136Pharmacokinetics and tolerability of Adjunctive Linezolid for the Treatment of tubERculous meningitis (ALTER): a Phase II trial, open-label, randomized trial (ATLER)9/11/2020Dr. Freddie Mukasa KibengoMRC/UVRI & London School of Hygiene and Tropical MedicineUniversity of California, San FranciscoOngoing24 Months
129.        0137Comparison of Mortality and Frequency of Red Blood Cell Allo-immunization in recipients of Leuko-reduced and Non-Leuko-reduced Blood Transfusion in Uganda.9/22/2020Dr. Clement Dove OkelloUganda Cancer InstituteUganda Cancer InstituteOngoing36 Months
130.        0138Randomized controlled non-inferiority trial of topical chlorhexidine 0.2% versus topical natamycin 5% for fungal keratitis in East Africa9/30/2020Dr. Simon ArungaMbarara University and Referral Eye CenterLondon School of Hygiene and Tropical MedicineOngoing36 Months
131.        0139The safety and imMunogeNicity of a combined Pertussis-cOntaining vaccine (Tdap) for HIV-infected pregnant WomEn and their newboRns-A Randomized Clinical Trial (woMANPOWER)9/23/2020Dr. Eva NakabembeMakerere University College of Health SciencesSt. Georges University of London, Joint Research and Enterprise ServicesOngoing24 Months
132.        0140An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19 12/27/2021Dr Juliet Mwanga-AmumpaireEpicentre Mbarara Research CentreDr. Rebecca F. GraisOngoing12 Months
133.        0141A randomized trial of 6 months intensified anti-tuberculosis and 2 months anti-inflammatory treatment for HIV-infected and HIV-uninfected African and Asian children with tuberculosis meningitis. (SURE STUDY)10/29/2020Dr. Eric WobudeyaMU-JHUUniversity College of LondonOngoing36 Months
134.        0142Optimizing DPT-containing vaccine infant immunization schedules in UGANDA. (OPTIMMS)2/4/2021Prof. Alison ElliotMRC/UVRIUniversity of OxfordOngoing48 Months
135.        0143The Efficacy and Safety of hydroxychloroquine for the treatment of non-severe covid-19 in adults in Uganda. A randomized open label phase II clinical trial (HONEST)9/9/2020Dr. Pauline Byakika-KibwikaMakerere University College of Health SciencesMakerere UniversityTerminated24 Months
136.        0144Effectives of low-dose Theophylline for the management of Biomass-associated COPD.12/10/2020Dr. Bruce KirengaMULINational Institute of HealthOngoing24 Months
137.        0145Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals by addressing Artemether-Lumefantrine and Efavirenz, A randomized Controlled Trial (OPTIMAL)3/11/2020Dr. Pauline Byakika-KibwikaMUCHSInfectious Diseases InstituteOngoing36 Months
138.        0146Assessment of safety and efficacy of COVID-19 Convalescent Plasma for treatment of COVID-19 in adults in Uganda; A phase III randomized controlled trial. (CCP)9/14/2020Dr. Bruce KirengaMULIMakerere UniversityOngoing5 Months
139.        0147Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A single Arm Open Label Trial. (BRAIN SAFE II)12/2/2020Dr. Richard IdroMUCHSGlobal Health Uganda, LimitedOngoing36 Months
140.        0148Pilot feasibility study for uptake and implementation of a clinical algorithm for warfarin dosing in sub-saharan African patients in the War-PATH Ugandan and South African Clinical study sites.1/8/2021Dr. Catriona WaittIDIUniversity of LiverpoolOngoing18 Months
141.        0149Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children with Sickle Cell Anemia in Eastern and Southern Africa. (CHEMCHA)11/19/2020Dr. Richard IdroMUCHSLiverpool School of Tropical Medicine, UKOngoing60 Months
142.        0150A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease.2/24/2021Dr. Henry DdunguUCIIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAOngoing36 Months
143.        0151A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease.2/24/2021Dr. Abner TagoolaJinja Regional Referral Hospital, Sickle Cell ClinicIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAOngoing36 Months
144.        0152A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease2/24/2021Dr. Victor MusiimeJCRCIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAOngoing36 Months
145.        0153A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease2/24/2021Dr. Afizi KibuukaIDRCIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAOngoing36 Months
146.        0154A Phase 2b study to evaluate the safety and efficacy of IMR-687 in subjects with sickle cell Disease2/24/2021Dr. Grace NdeeziMakerere College of Health Sciences/ Mulago HospitalIMARA, Inc C/O Eleanor Lisbon,MD,MPH Vice President, Clinical Development, IMARAOngoing36 Months
147.        0155An Open-Label, Roll-over study with Rilpivirine in Combination with a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies2/10/2021Dr. Francis SsaliJCRCJANSSEN Pharmaceuticals (Pty) LtdOngoing48 Months
148.        0156Multicenter, Adaptive, Randomized, Blinded Controlled Trial of safety and Efficacy of investigational Therapeutics for hospitalized patients with COVID-191/20/2021Dr. Joseph LutaakomeMRC/UVRI and LSHTMUniversity of MinnesotaOngoing36 Months
149.        0157Effect of Vitamin D supplementation on sickle cell disease hospitalization and related complications among children in Mulago Hospital: A randomized clinical trial2/22/2021Prof. Grace NdeeziDepartment of Pediatrics and Child HealthMakerere Research Innovation Fund (Mak RIF)Ongoing12 Months
150.        0158Safety and Pharmacokinetics of the combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults 2/17/2021Dr. Andrew MujugiraIDIInternational AIDS Vaccine InitiativeOngoing36 Months
151.        0159An Open-label, randomized, Single intravenous dosing to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers. (REMTLAR)2/12/2021Prof. Mohammed LamordeIDIInfectious Diseases InstituteOngoing12 Months
152.        0160Intensified tuberculosis treatment to reduce the mortality of HIV-Infected and HIV-uninfected patients with tuberculosis meningitis: a Phase III Randomized Controlled Trial. (INTENSE-TBM)4/8/2021Dr. Conrad K MuzooraMUSTProf. Francois DabisOngoing48 Months
153.        0161A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-Infected, Virological Suppressed Adults in Sub-Saharan Africa. (CARES)3/3/2021Dr. Cissy KityoJCRCJoint Clinical Research CentreOngoing39 Months
154.        0162The effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination8/18/2021Dr Cissy Kityo MutuluuzaJCRCUniversity of MinnesotaOngoing60 Months
155.        0163A clinical Evaluation of Efficacy, Safety, Immunogenicity and Tolerability of UBV-10N, A Natural Product in Adult Patients Infected with Sar-Cov-2 (Covid-19), In Uganda. (UBV-10N)1/25/2021Dr. Grace Nambatya KyeyuneDirector, Natural Chemotherapeutics Research InstitutePRESIDE (Presidential Scientific Initiative on Epidemics)Ongoing12 Months
156.        0164Safety and Pharmacokinetics of the combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults. (C100)3/24/2021Dr. Brenda OkechUVRI/IAVIInternational AIDS Vaccine Initiative (IAVI)Ongoing36 Months
157.        0165Pancreatic Enzymes and Bile Acids: A non-antibiotic approach to Treat Intestinal Dysbiosis in Acutely III Severely Malnourished Children. (PB SAM)9/15/2021Dr. Ezekiel MupereCWRUCUniversity of OxfordOngoing36 Months
158.        0166Paracetamol for Acute Renal Injury in Severe Malaria Trial (PARIST)8/24/2021Prof. Peter Olupot OlupotMbale Clinical Research InstituteMbale Clinical Research InstituteOngoing24 Months
159.        0167Identification, Validation & Optimization of available drug molecules for clinical treatment of COVID-19. (IVCOM)3/4/2021Dr. Jackson MukonzoDepartment of Pharmacology &TherapeuticsPresidential Scientific Initiative on EpidemicsOngoing12 Months
160.        0168A randomized Trial to investigate strategies to reduce mortality among HIV-Infected and HIV-exposed children admitted with severe acute malnutrition in Mulago Hospital, Kampala, Uganda. (REDMOTHIV)5/4/2021Dr. Victor MusiimeMakerere University College of Health SciencesMakerere University Research and Innovations FundOngoing36 Months
161.        0169A Phase II trial to describe the pharmacokinetics, safety and efficacy of pharmacogenetics-guided dosing of isoniazid in patients with HIV-associated TB (PHINX)9/13/2021Dr. Christine Sekaggya-WiltshireIDIMakerere UniversityOngoing24 Months
162.        0170Evaluation of pharmacokinetics, safety and feasibility for administration of two doses of intravenous ascorbic acid combined with vitamin B1 for the management of adult patients admitted with sepsis to Kiruddu National Referral Hospital. (REVISTA)6/8/2021Dr. Shevin JacobIDILiverpool School of Tropical MedicineOngoing12 Weeks
163.        0171A Phase 1 Trial of ChADOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern African. (HIV-CORE 006)6/4/2021Prof. Pontiano KaleebuMRC/UVRIUniversity of OxfordOngoing21 Months
164.        0172Gastroenteritis and Rehydration of children with Severe Acute Malnutrition (GASTROSAM)11/25/2021Prof. Peter Olupot-OlupotMCRIImperial College LondonOngoing24 Months
165.        0173Implementation of a bundle of care to improve anticoagulation control in patients receiving warfarin in Uganda and South Africa. (WARFARIN BUNDLE)7/19/2021Dr. Catriona WaittIDIUniversity of LiverpoolOngoing36 Months
166.        0174A multi-Centre, randomised, placebo controlled, double-blind, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine (GBS-NN/NN2) in women who are pregnant and living with HIV and women who are pregnant and do not have HIV. (MINERVAX)7/9/2021Dr. Musa SekikuboMU-JHUMinervaX A/SOngoing18 Months
167.        0175Finding Solutions to thrive after birth asphyxia in Africa: An open-label dose-finding clinical trial (Phase Ib study). SANE-Uganda.8/31/2021Dr. Nathan Kenya -MugishaWALIMUResearch Institute of the McGill University Health CentreOngoing18 Months
168.        0176A5372 Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals. (A5372)7/16/2021Dr. Cissy KityoJCRCNational Institute of Allergy and Infectious DiseasesClosed out12 Months
169.        0177A parallel-group, Phase III, multi-stage. Modified double-blind, multi-armed study to assess the efficacy, safety and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older. (VAT0008)8/11/2021Dr. Hannah KibuukaMUWRPSanofi Pasteur,IncOngoing24 Months
170.        0178An Open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose In Human Immunogenicity Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen. (EBOVAC BOOST)8/25/2021Prof. Pontiano KaleebuMRC/UVRI/LSHTMLSHTMOngoing6 Months
171.        0179B-ENHANCEMENT of HBV Vaccination in Persons Living With HIV (Bee-HIVe): Evaluation of HEPLISAV-B.10/8/2021Dr. Francis SsaliJCRCNIAIDOngoing30 Months
172.        0180A randomized clinical Trial of Early Empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in Sub-Saharan Africa (ATLAS trial)9/27/2021Dr. Conrad K. MuzooraMbarara University of Science and Technology (MUST), Mbarara Regional Referral Hospital National Institute of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID) Ongoing36 Months
173.        0181Efficacy and safety of artemether-lumefantrine, pyronaridine- Artesunate, Artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in children in Uganda11/9/2021Dr. Adoke YekaIDRCUSAIDOngoing24 Months
174.        0182A phase 1 Study to determine the safety and Immunogenicity of candidate Rift Valley Fever virus (RVFV) vaccine ChAdox1 among healthy adult volunteers in Uganda11/9/2021Dr. Irene Andia BiraroMakerere University College of Health SciencesNational Institute of Medical Research-Mbeya Medical Research CentreOngoing48 Months
175.        0183A Phase I study to determine the safety and immunogenicity of the candidate Rift Valley Fever Virus (RVFV) vaccine ChAdOx1 RVF among healthy adult volunteers in Uganda. ( RVF002)9/29/2021Prof. Pontiano KaleebuMRC/UVRI LSHTM Uganda Research Unit, Masaka site.Dr. Stephen ConwayJust acquired NDA approval12 weeks from date of enrollment of the last volunteer (s)
176.        0184Phase I/II study of the Safety, Acceptability. Tolerability and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. (IMPAACT 2017)11/12/2021Dr. Violet KorutaroBaylor College of Medicine Children’s FoundationNational Institute of Allergy and Infectious Disease Institute and Eunice Kennedy Shriver, National Institute of Child Health and Human Development. National Institute of Mental HealthOngoing84 Months
177.        0185DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children with HIV Infection Aged 2 to <15 Years Old (D3: PENTA 21)10/7/2021Dr. Cissy KityoJCRCFondazione PENTA ONLUSOngoing60 Months (5 years)
178.        0186A clinical trial to assess the safety and immunogenicity of a modified self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19, in SARS-CoV-2 seronegative and seropositive Ugandan population (COVAC)9/14/2021Prof. Pontiano KaleebuMRC/UVRI LSHTM Uganda Research UnitImperial College LondonOngoing10 Months
179.        0187Drug Interactions between Dolutegravir (DTG) and escalating-doses of Rifampicin (RIF) Study12/13/2021Dr. Mohammed LamordeIDIUniversity of LiverpoolOngoing24 Months
180.        0189An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyper immune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19. (OTAC)11/17/2021Dr. Joseph LutaakomeMRC/UVRI LSHTM Uganda Research UnitUniversity of MinnesotaOngoing36 Months
181.        0190Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccines in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)9/16/2021Dr. Cissy KityoJCRCSouth African Medical Research Council (SAMRC)Ongoing14 Months
182.        0191Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccines in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)9/20/2021Dr. Deo WabwireMU-JHUSouth African Medical Research Council (SAMRC)Ongoing14 Months
183.        0192Phase I/II study of the Safety, Acceptability. Tolerability and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. (IMPAACT 2017)11/8/2021Dr. Maxensia OworMU-JHUDivision of AIDS (DAIDS)Ongoing84 Months
184.        0193Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)9/16/2021Dr. Peter James ElyanuBAYLORSouth African Medical Research Council (SAMRC)Ongoing14 Months
185.        0194Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. (CoVPN 3008)9/17/2021Dr. Annet NanvubyaUVRI/IAVISouth American Medical Research Council (SAMRC)Ongoing14 Months
186.        0195A phase 3, randomized, active-controlled, double-blind clinical study to evaluate the efficacy and safety of oral Islatravir once-monthly as pre-exposure prophylaxis in cisgender women at high risk for HIV-1 infection. (MK-8591-022/ IMPOWER-022)10/19/2021Dr. Brenda Gati MirembeMU-JHUMerck Sharp & Dohme corp. a subsidiary of Merck & Co. IncOngoing48 Months
187.        0196Enhancing Immunity to Malaria in YoungChildren with effective Chemoprevention (MIC-DROP)12/3/2021Prof. Moses KamyaIDRCNational Institute of Child Health and Human DevelopmentOngoing60 Months
188.        0200A Phase 3 Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis Adolescent Girls and Young Women at Risk of HIV Infection. (PURPOSE-1)12/1/2021Dr. Flavia Matovu KiweewaMU-JHUGilead Sciences. IncOngoing72 Months
189.        0201A randomized open-label 2-arm, 96-week trial evaluate the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-saharan Africa (Breather Plus)12/13/2021Dr. Adeodata R KekitiinwaBaylorUniversity College of London (UCL), UKOngoing60 Months
190.        0203A Multicenter, prospective, randomized, placebo controlled, openlabel, stepped wedge clinical trial of respiratory support with continuous positiveairway pressure or high flow Oxygen therapy in adults with acute hypoxemic respiratory distress in Sub-Saharan Africa. (ARISE)12/14/2021Dr Arthur KwizeraDepartment of Anaesthesia and Critical Care Makerere University College of Health SciencesOngoing15 Months

*TBC= To Be Confirmed

Abbreviations

1. MUCHS           Makerere University College of Health Sciences
2. MU-JHU          Makerere University – John Hopkins University
3. MU-UCSF        Makerere University – University of California, San Francisco

4. MRC/UVRI       Medical Research Council / Uganda Virus Research Institute
5. UVRI-IAVI        Uganda Virus Research Institute – International AIDS Vaccine Initiative
6. LSHTM            London School of Hygiene and Tropical Medicine

7. MUST             Mbarara University School of Science & Technology

8. MUWRP         Makerere University Walter Reed Project

9. CWRURC        Case Western Reserve University Research Collaboration

10. IDI                 Infectious Disease Institute

11. IDRC             Infectious Disease Research Collaboration